Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16
The DOI matches its Crossref record; 26 of the 28 references it cites were found in a registry or an index.
Abstract
D-type cyclins, in association with the cyclin-dependent kinases Cdk4 or Cdk6, promote progression through the G1 phase of the cell cycle by phosphorylating the retinoblastoma protein (RB). The activities of Cdk4 and Cdk6 are constrained by inhibitors such as p16, the product of the CDKN2 gene on human chromosome 9p21 (refs 12-14). The frequent deletion or mutation of CDKN2 in tumour cells suggests that p16 acts as a tumour suppressor. We show that wild-type p16 arrests normal diploid cells in late G1, whereas a tumour-associated mutant of p16 does not. Significantly, the ability of p16 to induce cell-cycle arrest is lost in cells lacking functional RB, including primary fibroblasts from Rb-/- mouse embryos. Thus, loss of p16, overexpression of D-cyclins and loss of RB have similar effects on G1 progression, and may represent a common pathway to tumorigenesis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Importantly, cells lacking functional RB were resistant to p16INK4a-mediated cell cycle arrest, implying that the ability of CDK4 (and later, CDK6) to drive G1 phase progression required RB (33-35) and predicting that chemical CDK4/6 inhibitors would show efficacy only if RB were functionally intact.”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [33]
Citations
Cites
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650
A cell cycle regulator potentially involved in genesis of many tumor types
Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S., Johnson, B. E., & Skolnick, M. H. (1994) · Science · doi:10.1126/science.8153634 · Cited by 2,751
G1 phase progression: Cycling on cue
Sherr, C. J. (1994) · Cell · doi:10.1016/0092-8674(94)90540-1 · Cited by 2,674
Cyclins and cancer II: Cyclin D and CDK inhibitors come of age
Hunter, T., & Pines, J. (1994) · Cell · doi:10.1016/0092-8674(94)90543-6 · Cited by 2,091
pl5INK4B is a potentia| effector of TGF-β-induced cell cycle arrest
Hannon, G. J., & Beach, D. (1994) · Nature · doi:10.1038/371257a0 · Cited by 1,950
Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers
Nobori, T., Miura, K., Wu, D. J., Lois, A., Takabayashi, K., & Carson, D. A. (1994) · Nature · doi:10.1038/368753a0 · Cited by 1,742
Cyclin D1 is a nuclear protein required for cell cycle progression in G1
Baldin, V, Lukas, J., Marcote, M. J., Pagano, M., & Draetta, G. (1993) · Genes & Development · doi:10.1101/gad.7.5.812 · Cited by 1,614
Self-citation(1993) · Genes & Development · doi:10.1101/gad.7.3.331 · Cited by 1,264
Distinct Roles for Cyclin-Dependent Kinases in Cell Cycle Control
van den Heuvel, S., & Harlow, E. (1993) · Science · doi:10.1126/science.8266103 · Cited by 1,092
Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts.
Quelle, D. E., Ashmun, R. A., Shurtleff, S. A., Kato, J. Y., Bar-Sagi, D., Roussel, M. F., & Sherr, C. J. (1993) · Genes & Development · doi:10.1101/gad.7.8.1559 · Cited by 1,032
Research works printed but not linked: 8
- Jiang, W. et al. Oncogene 8, 3447–3457 (1993).
- Lukas, J., Pagano, M., Staskova, Z., Draetta, G. & Bartek, J. Oncogene 9, 707–718 (1994).
- Jen, J. et al. Cancer Res. 54, 6353–6358 (1994).
- Li, Y., Nichols, M. A., Shay, J. W. & Xiong, Y. Cancer Res. 54, 6078–6082 (1994).
- Otterson, G. A., Kratzke, R. A., Coxon, A., Kim, Y. W. & Kaye, F. J. Oncogene 9, 3375–3378 (1994).
- Tam, S. W. Shay, J. W. & Pagano, M. Cancer Res. 54, 5816–5820 (1994).
- Ohta, M. et al. Cancer Res. 54, 5269–5272 (1994).
- Lukas, J. et al. Oncogene (in the press).
Cited by
Items 401–500 of 902
Shi, Y.-Z., Hui, A., Li, X., Takayama, T., & Makuuchi, M. (2000) · PubMed · Cited by 53
p16INK4a protects against dysfunctional telomere–induced ATR-dependent DNA damage responses
Wang, Y., Sharpless, N., & Chang, S. (2013) · Journal of Clinical Investigation · doi:10.1172/jci69574 · Cited by 48
“…and p53/p21 pathways are involved in the activation of cellular senescence. p16 INK4a is a potent inhibitor of the kinase activities of CDK4/6, resulting in Rb hypophosphorylation, binding to E2F1, the initiation of cell cycle arrest in the G1 phase, and the onset of cellular senescence (53–55).”
Lahti, J. M., Li, H., & Kidd, V. J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.16.10859 · Cited by 50
Methylation of the p16INK4A gene in multiple myeloma
Tasaka, T., Asou, H., Munker, R., Said, J. W., Berenson, J., Vescio, R. A., Nagai, M., Takahara, J., & Koeffler, H. P. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00724.x · Cited by 49
“This prevents phosphorylation of pRb by maintaining a growth-suppressing state, which results in the blockade of the cell cycle between G1 and S (Guan et al, 1994; Medema et al, 1995; Koh et al, 1995; Lukas et al, 1995; Arap et al, 1995).”
BackgroundKannengiesser, C., Brookes, S., del Arroyo, A. G., Pham, D., Bombled, J., Barrois, M., Mauffret, O., Avril M, M.-F., Chompret, A., Lenoir, G. M., et al. (2009) · Human Mutation · doi:10.1002/humu.20845 · Cited by 41
“It is also difficult to reconcile these observations with the consistent evidence that p16INK4A-mediated cell cycle arrest requires a functional retinoblastoma protein [Koh et al., 1995; Lukas et al., 1995; Medema et al., 1995].”
BackgroundSelf-citationCyclin D3 Is Rate-limiting for the G1/S Phase Transition in Fibroblasts
Herzinger, T., & Reed, S. I. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.24.14958 · Cited by 49
Nordengren, J., Casslén, B. G., Gustavsson, B., Einarsdottir, M., & Wïllén, R. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19980417)79:2<187::aid-ijc15>3.0.co;2-7 · Cited by 14
Jiang, J., Gu, Y., Liu, J., Wu, R., Fu, L., Zhao, J., & Guan, Y. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.10.015 · Cited by 47
Melanoma Susceptibility Genes and Risk Assessment
Marzuka-Alcalá, A., Gabree, M., & Tsao, H. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-727-3_20 · Cited by 50
Jour, G., West, K., Ghali, V. S., Shank, D. L., Ephrem, G., & Wenig, B. M. (2013) · Head and Neck Pathology · doi:10.1007/s12105-012-0417-9 · Cited by 47
The Retinoblastoma Gene Family in Cell Cycle Regulation and Suppression of Tumorigenesis
Dannenberg, J.-H., & te Riele, H. P. J. (2006) · Results and Problems in Cell Differentiation · doi:10.1007/400_002 · Cited by 47
Methylation, expression, and mutation analysis of the cell cycle control genes in human brain tumors
Yin, D., Xie, D., Hofmann, W., Miller, C. W., Black, K. L., & Koeffler, H. P. (2002) · Oncogene · doi:10.1038/sj.onc.1206031 · Cited by 49
“…Kamb et al., 1994b). p16INK4A and p15INK4B are tumor suppressors that induce a G1 cell cycle arrest by inhibiting the activity of cyclin dependent kinases 4 and 6 (CDK4 and CDK6) to phosphorylate the RB protein (Lukas et al., 1995; Koh et al., 1995; Serrano et al., 1993; Hannon and Beach, 1994).”
BackgroundCyclin D3 Regulates Proliferation and Apoptosis of Leukemic T Cell Lines
Boonen, G. J. J. C., van Oirschot, B. A., van Diepen, A., Mackus, W. J. M., Verdonck, L. F., Rijksen, G., & Medema, R. H. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.49.34676 · Cited by 48
The molecular significance of methylated BRCA1 promoter in white blood cells of cancer-free females
Al‐Moghrabi, N., Nofel, A., Al‐Yousef, N., Madkhali, S., Amer, S. M. B., Alaiya, A. A., Shinwari, Z., Al‐Tweigeri, T., Karakas, B., Tulbah, A. M., et al. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-830 · Cited by 46
A p18 mutant defective in CDK6 binding in human breast cancer cells.
Lapointe, J., Lachance, Y., Labrie, Y., & Labrie, C. (1996) · PubMed · Cited by 46
Expressions of Cell Cycle Regulators in Human Colorectal Cancer Cell Lines
Tominaga, O., Nita, M. E., Nagawa, H., Fujii, S., Tsuruo, T., & Muto, T. (1997) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1997.tb00461.x · Cited by 49
p16 protein expression is associated with a poor prognosis in squamous cell carcinoma of the lung
Huang, C.-I., Taki, T., Higashiyama, M., Kohno, N., & Miyake, M. (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.0929 · Cited by 49
“The p16 protein binds both cdk4 and cdk6, and negatively regulates the cyclin D-dependent phosphorylation of the RB protein, thereby inhibiting the cell cycle transition from G1 to S phase by sequestering of a transactivation factor of E2F (Serrano et al, 1993; Lukas et al, 1995).”
BackgroundConserved RB functions in development and tumor suppression
Gordon, G. M., & Du, W. (2011) · Protein & Cell · doi:10.1007/s13238-011-1117-z · Cited by 53
Osteosarcoma of the jaws: An overview of the pathophysiological mechanisms
Bertin, H., Gomez‐Brouchet, A., & Rédiní, F. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103126 · Cited by 47
“P16 is a cyclin-dependent kinase inhibitor encoded by the CDKN2A gene that is involved in regulation of the cell cycle by inhibition of the transition from G1 to S phase of the cell cycle (Lukas et al., 1995) (Fig.”
Korkolopoulou, P. A., Christodoulou, P. N., Lazaris, A. C., Thomas-Tsagli, E., Kapralos, P., Papanikolaou, A., Kalliteraki, I., & Davaris, P. S. (2001) · European Urology · doi:10.1159/000052432 · Cited by 45
“Along this line it has been hypothesized that deletions of both regulators may be functionally redundant, since either p16 or pRb loss has similar effects on G 1 progression. Nevertheless, because pRb lies downstream of p16 (and cyclin D 1 ), abrogation of either p16 (or cyclin D 1 ) activity is likely to have no effe…”
Backgroundp16INK4a and p21Waf1/Cip1 expression correlates with clinical outcome in vulvar carcinomas
Knopp, S., Bjørge, T., Nesland, J. M., Trope, C. G., Scheistrøen, M., & Holm, R. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2004.07.026 · Cited by 45
Cui, X., Shirai, Y., Wakai, T., Yokoyama, N., Hirano, S., & Hatakeyama, K. (2004) · Human Pathology · doi:10.1016/j.humpath.2004.06.010 · Cited by 45
Akama, Y., Yasui, W., Kuniyasu, H., Yokozaki, H., Akagi, M., Tahara, H., Ishikawa, T., & 田原, 榮. (1996) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1996.tb02106.x · Cited by 46
Hashemi, J., Bendahl, P., Sandberg, T., Platz, A., Linder, S., Stierner, U., Olsson, H., Ingvar, C., Hansson, J., & Borg, Å. (2001) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.1124 · Cited by 45
“The CDKN2A product, p16-INK4A, has been identified as an inhibitor of cyclin-dependent kinases CDK4 and CDK6 (Serrano et al., 1993; Lukas et al., 1995) and induces cell-cycle G1-phase arrest by preventing the association of these kinases with D-type cyclins, thereby inhibiting phosphorylation of…”
BackgroundKurasono, Y., Ito, T., Kameda, Y., Nakamura, N., & Kitamura, H. (1998) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s004280050157 · Cited by 45
Wang, T.-J., Huang, M.-S., Hong, C.-Y., Tse, V., Silverberg, G. D., & Hsiao, M. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.5565 · Cited by 44
Regulation of cell cycle molecules by the Ras effector system
Takuwa, N., & Takuwa, Y. (2001) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(01)00439-7 · Cited by 44
“Thus, overexpression of p16INK4a, which is a CDK inhibitor that specifically acts on D type cyclin-CDKs and a tumor suppressor frequently lost or mutated in human tumors, inhibits oncogenic Ras-induced cell proliferation (Serrano et al., 1995), only when wild type Rb is present ( Lukas et al., 1995 ).”
BackgroundCDKN2A as a uveal and cutaneous melanoma susceptibility gene
Kannengiesser, C., Avril, M., Spatz, A., Laud, K., Lenoir, G., & Paillerets, B. B. (2003) · Genes Chromosomes and Cancer · doi:10.1002/gcc.10286 · Cited by 44
“CDKN2A expression causes cells to arrest in the G1 phase of the cell cycle by pRb inactivation (Lukas et al., 1995), whereas ARF interacts with HDM2, thereby promoting TP53 degradation and a cell cycle arrest in G1 and G2 (Stott et al., 1998).”
Backgroundp16/MTS1/INK4A suppresses prostate cancer by both pRb dependent and independent pathways
Steiner, M. S., Wang, Y., Zhang, Y., Zhang, X., & Lu, Y. W. (2000) · Oncogene · doi:10.1038/sj.onc.1203428 · Cited by 46
“Induction of senescence by p16 required wild-type pRb Rb has been proposed as a downstream component of the p16 pathway (Lukas et al., 1995; Kratzke et al., 1996; Foulkes et al., 1997; Haas et al., 1997).”
BackgroundFrequent alteration of CDKN2 (p16(INK4A)/MTS1) expression in human primary prostate carcinomas.
Chi, S. G., White, R. D., Muenzer, J. T., & Gumerlock, P. H. (1997) · PubMed · Cited by 53
RB Reversibly Inhibits DNA Replication via Two Temporally Distinct Mechanisms
Angus, S. P., Mayhew, C. N., Solomon, D. A., Braden, W. A., Markey, M. P., Okuno, Y., Cardoso, M. C., Gilbert, D. M., & Knudsen, E. S. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.12.5404-5420.2004 · Cited by 48
“The p16ink4a CDK inhibitor is known to elicit an RB-dependent cell cycle arrest ( 40 , 61).”
BackgroundHavrilesky, L. J., Secord, A. A., Whitaker, R. S., Marks, J. R., & Berchuck, A. (2001) · Gynecologic Oncology · doi:10.1006/gyno.2001.6464 · Cited by 47
Promoter methylation and loss of p16INK4a gene expression in head and neck cancer
Demokan, S., Chuang, A., Süoğlu, Y., Ulusan, M., Yalniz, Z., Califano, J. A., & Dalay, N. (2011) · Head & Neck · doi:10.1002/hed.21949 · Cited by 48
“The gene is located on chromosome 9p21 and its product (also called CDKN2A) prevents phosphorylation of the retinoblastoma tumor suppressor gene by repressing the catalytic activity of cdk4-cdk6/cyclin D enzyme complex.(7) Methylation of tumor suppressor genes plays a significant role in head and neck carcinogenesis a…”
BackgroundEvangelou, K., Bramis*, J., Peros, I., Zacharatos, P., Dasiou-Plakida, D., Kalogeropoulos, N., Asimacopoulos, P., Kittas, C., Marinos, E., & Gorgoulis, V. (2004) · Biotechnic & Histochemistry · doi:10.1080/10520290310001659466 · Cited by 44
“Furthermore, the strongly positive cytoplasmic p16INK4A signal reported in bladder and breast cell lines, as assessed by immunofluoresence, strengthens the notion that cytoplasmic staining is specific and not an artifact owing to fixation (Lukas et al. 1995).”
BackgroundAnalysis of the p16INK4 and TP53 tumor suppressor genes in bone sarcoma pediatric patients
Patiño‐García, A., & Sierrasesúmaga, L. (1997) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(96)00397-4 · Cited by 43
Cheng, L., Rossi, F., Fang, W., Mori, T., & Cobrinik, D. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m005707200 · Cited by 43
Hamam, D., Abdouh, M., Gao, Z., Arena, V., Arena, M., & Arena, G. O. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0360-9 · Cited by 43
Biomarkers of head and neck cancer, tools or a gordian knot?
Lampri, E. S., Chondrogiannis, G., Ioachim, E. E., Varouktsi, A., Mitselou, A., Galani, A., Briassoulis, E., Kanavaros, P., & Galani, V. (2015) · PubMed · Cited by 50
Kim, C., Terado, T., Tambe, Y., Mukaisho, K., Sugihara, H., Kawauchi, A., & Inoue, H. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.4194 · Cited by 45
Al‐Khalaf, H. H., Mohideen, P., Nallar, S. C., Kalvakolanu, D. V., & Aboussekhra, A. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.512640 · Cited by 45
Huhn, S. L., Mohapatra, G., Bollen, A. W., Lamborn, K. R., Prados, M. D., & Feuerstein, B. G. (1999) · PubMed · Cited by 45
Gupta, S., Bakhshi, S., Kumar, L., Kamal, V. K., & Kumar, R. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1193855 · Cited by 41
“The CDKN2B gene codes for another cell cycle inhibitor p15.[18] Most of our patients had loss of both A & B domains.”
BackgroundThe role of tumor DNA as a diagnostic tool for head and neck squamous cell carcinoma
Chan, J. Y. K., Gooi, Z., & Agrawal, N. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.07.008 · Cited by 46
Yu, B. D., Becker-Hapak, M., Snyder, E. L., Vooijs, M., Denicourt, C., & Dowdy, S. F. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2431391100 · Cited by 42
Konstantinidis, A. K., Radhakrishnan, R., Gu, F., Rao, R. N., & Yeh, W. K. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.41.26506 · Cited by 41
Kawabe, S., Roth, J. A., Wilson, D. R., & Meyn, R. E. (2000) · Oncogene · doi:10.1038/sj.onc.1203935 · Cited by 43
“Similarly, p16INK4a inhibits the ability of CDK4 and CDK6 to regulate the phosphorylation status of pRb, thereby also controlling progression into S phase (Lukas et al., 1995; Serrano et al., 1993).”
BackgroundRole of the retinoblastoma tumor suppressor protein in cellular differentiation
Nguyen, D. X., & McCance, D. J. (2005) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20375 · Cited by 40
“This model is supported by studies in which the cytostatic effects of upstream components of the Rb pathway such as the CDK inhibitor p16INK4A, also requires intact pocket protein function [Lukas et al., 1995; Medema et al., 1995].”
MethodWnt Signaling Has Opposing Roles in the Developing and the Adult Brain That Are Modulated by Hipk1
Marinaro, C., Pannese, M., Weinandy, F., Sessa, A., Bergamaschi, A., Taketo, M. M., Broccoli, V., Comi, G., Götz, M., Martino, G., et al. (2012) · Cerebral Cortex · doi:10.1093/cercor/bhr320 · Cited by 39
“Finally, we observed that the active form of b-Catenin induces the expression of the p16INK4a in aNPCs of the SVZ (Lukas et al. 1995).”
BackgroundCDKN2A Germline Rare Coding Variants and Risk of Pancreatic Cancer in Minority Populations
McWilliams, R. R., Wieben, E. D., Chaffee, K. G., Antwi, S. O., Raskin, L., Olopade, O. I., Li, D., Highsmith, W. E., Colon-Otero, G., Khanna, L. G., et al. (2018) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-17-1065 · Cited by 37
“Both p16 and p14 appear to suppress tumorigenesis (62, 63).”
BackgroundNon-Invasive Biomarkers for Early Lung Cancer Detection
Saman, H. T., Raza, A., Patil, K., Shahab Uddin, M. S., & Crnogorac‐Jurcevic, T. (2022) · Cancers · doi:10.3390/cancers14235782 · Cited by 42
Węsierska‐Gądek, J., & HORKYA, M. (2003) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1299.046 · Cited by 48
Costanzi-Strauss, E., Strauss, B. E., Naviaux, R. K., & Haas, M. (1998) · Experimental Cell Research · doi:10.1006/excr.1997.3810 · Cited by 44
Calbó, J., Marotta, M., Cascalló, M., Roig, J. M., Gelpí, J. L., Fueyo-Margareto, J., & Mazo, A. (2001) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700374 · Cited by 40
Frequent p16INK4 (MTS1) gene inactivation in testicular germ cell tumors.
Chaubert, P., Guillou, L., Kurt, A.-M., Mm, B., Metthez, G., Leisinger, H., Bosman, F. T., & Shaw, P. H. (1997) · Europe PMC (PubMed Central) · Cited by 46
Hommura, F., Dosaka‐Akita, H., Kinoshita, I., Mishina, T., Hiroumi, H., Ogura, S., Katoh, H., & Kawakami, Y. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690750 · Cited by 40
“…cell cycle progression at the G1 checkpoint, tion in a single regulatory pathway of the cell cycle and tum suppression (Serrano et al, 1993; Lukas et al, 1995), a conc supported by the findings of inverse correlations between a ation of both proteins in several types of cancer, including…”
Backgroundp16INK4A as a human tumor suppressor
Shapiro, G. I., & Rollins, B. J. (1996) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(95)00011-4 · Cited by 44
Telomere uncapping during in vitro T‐lymphocyte senescence
Chebel, A., Bauwens, S., Gerland, L., Belleville, A., Urbanowicz, I., De Climens, A. R., Tourneur, Y., Chien, W. W., Catallo, R., Salles, G., et al. (2009) · Aging Cell · doi:10.1111/j.1474-9726.2008.00448.x · Cited by 37
Melanoma Genetics: An Update on Risk-Associated Genes
Udayakumar, D., & Tsao, H. (2009) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2009.03.011 · Cited by 44
Bandara, L. R., Girling, R., & Thangue, N. B. L. (1997) · Nature Biotechnology · doi:10.1038/nbt0997-896 · Cited by 45
Malanchi, I., Caldeira, S., Krützfeldt, M., Giarrè, M., Alunni‐Fabbroni, M., & Tommasino, M. (2002) · Oncogene · doi:10.1038/sj.onc.1205617 · Cited by 39
“Its ectopic expression leads to an accumulation of hypophosphorylated pRb, sequestration of E2F and consequent G1 arrest (Lukas et al., 1995).”
BackgroundActive RB Elicits Late G1/S Inhibition
Angus, S. P., Fribourg, A. F., Markey, M. P., Williams, S., Horn, H. F., DeGregori, J. V., Kowalik, T. F., Fukasawa, K., & Knudsen, E. S. (2002) · Experimental Cell Research · doi:10.1006/excr.2002.5510 · Cited by 45
Prognostic value of p16 expression in Epstein‐Barr virus–positive nasopharyngeal carcinomas
Jiang, W., Chamberlain, P. D., Garden, A. S., Kim, B. Y. S., Ma, D., Lo, E. J., Bell, D., Gunn, G. B., Fuller, C. D., Rosenthal, D. I., et al. (2015) · Head & Neck · doi:10.1002/hed.24258 · Cited by 38
D’Amico, M., Wu, K., Fu, M., Rao, M., Albanese, C., Russell, R. G., Lian, H., Bregman, D. B., White, M. A., & Pestell, R. G. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2519 · Cited by 45
“corresponds to a repression of E2F-regulated genes (36, 63, 64).”
The Structure of the Vertebrate Lens
Kuszak, J. R., & Costello, M. J. (2004) · Cambridge University Press eBooks · doi:10.1017/cbo9780511529825.005 · Cited by 40
The regulation of cyclin-dependent kinase inhibitors (CKIs)
Peter, M. (1997) · Springer eBooks · doi:10.1007/978-1-4615-5371-7_8 · Cited by 42
Peeper, D. S., & Bernards, R. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)00319-0 · Cited by 36
Kr̨ecicki, T., Śmigiel, R. S., Frączek, M., Kowalczyk, M., & Sasiadek, M. M. (2004) · The Journal of Laryngology & Otology · doi:10.1258/0022215042244769 · Cited by 36
Braden, W. A., Lenihan, J. M., Lan, Z., Luce, K. S., Zagorski, W., Bosco, E., Reed, M. F., Cook, J. G., & Knudsen, E. S. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00045-06 · Cited by 35
“Saos-2 human osteosarcoma cells express a mutant nonfunctional RB but also express endogenous p16ink4a (1, 38 ).”
BackgroundInfluentialRetractedSpillare, E. A., Okamoto, A., Hagiwara, K., Demetrick, D. J., Serrano, M., Beach, D., & Harris, C. C. (1996) · Molecular Carcinogenesis · doi:10.1002/(sici)1098-2744(199605)16:1<1::aid-mc1>3.0.co;2-n · Cited by 36
Cytoplasmic, but not nuclear, p16 expression may signal poor prognosis in high-grade astrocytomas
Arifin, M. T., Hama, S., Kajiwara, Y., Sugiyama, K., Saito, T., Matsuura, S., Yamasaki, F., Arita, K., & Kurisu, K. (2006) · Journal of Neuro-Oncology · doi:10.1007/s11060-005-9037-5 · Cited by 39
“As p16 inhibits the ability of CDK4 and CDK6 to regulate the phosphorylation status of pRb, p16 plays a role in progression to the S phase [5,6].”
BackgroundCoskun, V., Venkatraman, G., Yang, H., Rao, M. S., & Luskin, M. B. (2001) · International Journal of Developmental Neuroscience · doi:10.1016/s0736-5748(00)00092-7 · Cited by 37
“The hypophosphorylated form of Rb inhibits the cell cycle at the G1 phase, by remaining bound to the transcription factor E2F and preventing cell cycle progression to the S phase (Kato et al., 1993; Lukas et al., 1995; Weinberg, 1995).”
BackgroundHomozygous deletions of the CDKN2/p16 gene in dural hemangiopericytomas
Ono, Y., Ueki, K., Joseph, J. T., & Louis, D. N. (1996) · Acta Neuropathologica · doi:10.1007/s004010050419 · Cited by 38
“The CDKN2/p16 gene encodes p16, an inhibitor of the cdk4/cyclin D1 complexes that in turn inhibit the pRb protein, which negatively regulates the G1/S transition of the cell cycle; loss of p16 function, therefore, leads to deregulated progression into S phase [17, 22 , 23, 31].”
BackgroundTargeting hyperproliferative disorders with cyclin dependent kinase inhibitors
Rosania, G. R., & Chang, Y. (2000) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.10.2.215 · Cited by 43
“In growth arrested cells, the INK4 proteins can act upstream of Rb, precluding Rb phosphorylation by CDK4/cyclin D complexes [33,34,37-39].”
BackgroundDependency of Cholangiocarcinoma on Cyclin D–Dependent Kinase Activity
Sittithumcharee, G., Suppramote, O., Vaeteewoottacharn, K., Sirisuksakun, C., Jamnongsong, S., Laphanuwat, P., Suntiparpluacha, M., Matha, A., Chusorn, P., Buraphat, P., et al. (2019) · Hepatology · doi:10.1002/hep.30704 · Cited by 39
“As documented,(26) up-regulation of p16 is common in pRB-negative cells.”
BackgroundAlhaja, E., Adán, J., Pagan, R., Mitjans, F., Cascalló, M., Rodríguez, M., Noé, V., Ciudad, C. J., Mazo, A., Vilaró, S., et al. (2004) · Angiogenesis · doi:10.1007/s10456-005-0368-9 · Cited by 35
p16INK4a and beta-catenin alterations in rat liver tumors induced by NNK
Pulling, L. C. (2001) · Carcinogenesis · doi:10.1093/carcin/22.3.461 · Cited by 35
Genetic Determinants of Cutaneous Melanoma Predisposition
Udayakumar, D., Mahato, B., Gabree, M., & Tsao, H. (2010) · Seminars in Cutaneous Medicine and Surgery · doi:10.1016/j.sder.2010.06.002 · Cited by 45
Aoki, S., Kong, D., Matsui, K., & Kobayashi, M. (2004) · Anti-Cancer Drugs · doi:10.1097/00001813-200404000-00009 · Cited by 34
N-acetyl transferase 2 genotypes, meat intake and breast cancer risk
Gertig, D. M., Hankinson, S. E., Hough, H., Spiegelman, D., Colditz, G. A., Willett, W. C., Kelsey, K. T., & Hunter, D. J. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990105)80:1<13::aid-ijc3>3.0.co;2-w · Cited by 101
Control of retinoblastoma protein-independent hematopoietic cell cycle by the pRB-related p130
Hoshikawa, Y., Mori, A., Amimoto, K., Iwabe, K., & Hatakeyama, M. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.15.8574 · Cited by 34
Novel approaches to the treatment of non-small cell lung cancer
Ferreira, C. G., Huisman, C., & Giaccone, G. (2002) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(01)00197-4 · Cited by 33
Berman, H. K., Gauthier, M. L., & Tlsty, T. D. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0073 · Cited by 36
The Cell Cycle: Accelerators, Brakes, and Checkpoints
Ivanchuk, S. M., & Rutka, J. T. (2004) · Neurosurgery · doi:10.1227/01.neu.0000109534.28063.5d · Cited by 43
“Evidence for the role of D-type cyclins in driving cells through G1 was derived from studies with experimental cell culture systems, in which it was demonstrated that cyclin D1 overexpression was sufficient to enable G1 progression (46).”
BackgroundYang, J., Luan, J., Yu, Y., Li, C., DePinho, R. A., Chin, L., & Richmond, A. J. (2001) · PubMed · Cited by 35
E2Fs and the Retinoblastoma Protein Family
Sardet, C., Cam, L. L., Fabbrizio, E., & Vidal, M. (1997) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-8934-6_1 · Cited by 37
Cell Cycle Control in Fission Yeast and Mammals: Identification of New Regulatory Mechanisms
Okayama, H., Nagata, A., Jinno, S., Murakami, H., Tanaka, K., & Nakashima, N. (1996) · Advances in cancer research · doi:10.1016/s0065-230x(08)60859-3 · Cited by 34
Chao, D. L., Maley, C. C., Wu, X., Farrow, D. C., Galipeau, P. C., Sanchez, C. A., Paulson, T. G., Rabinovitch, P. S., Reid, B. J., Spitz, M. R., et al. (2006) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-06-0492 · Cited by 32
The RB Protein Family in Retinal Development and Retinoblastoma: New Insights from New Mouse Models
Bremner, R., Chen, D., Pacal, M., Livne‐Bar, I., & Agochiya, M. (2004) · Developmental Neuroscience · doi:10.1159/000082284 · Cited by 37
Molecular and cellular pathology of intrinsic brain tumours
Merzak, A., & Pilkington, G. J. (1997) · Cancer and Metastasis Reviews · doi:10.1023/a:1005760726850 · Cited by 35
Ellsworth, R. E., Hooke, J. A., Love, B., Kane, J. L., Patney, H. L., Ellsworth, D. L., & Shriver, C. D. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9547-2 · Cited by 31
“The high frequency of alterations at 9p21, 11q23 and 17p13.1 suggest these regions are part of the genetic pathway discriminating grade 1 from grade 3 disease (Fig. 3). None of these regions has previously been implicated in the grade 3 genetic pathway, however, the CDKN2A gene on 9p21 encodes the p16 protein, loss of…”
BackgroundCell Cycle Regulation in Treatment of Breast Cancer
Cai, Z., & Liu, Q. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-6020-5_12 · Cited by 37
Psoriatic epidermis is associated with upregulation of CDK 2 and inhibition of CDK 4 activity
Henri, P., Prével, C., Pellerano, M., Lacotte, J., Stoebner, P., Morris, M. C., & Meunier, L. (2019) · British Journal of Dermatology · doi:10.1111/bjd.18178 · Cited by 32
DeWire-Schottmiller, M. D., Fuller, C. E., Campagne, O., Lin, T., Pan, H., Poussaint, T. Y., Baxter, P. A., Hwang, E. I., Bukowinski, A., Dorris, K. M. O., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4078 · Cited by 34
“Ribociclib (LEE011, Novartis Pharmaceuticals) is an orally bioavailable CDK 4/6 inhibitor and induces G1-phase cell-cycle arrest by hypophosphorylation of Rb, demonstrating dependence on a functional Rb protein for efficacy (24, 25).”
BackgroundCheng, W., Lin, T., Tseng, Y., Chu, F., Chueh, P. J., Kuo, Y., & Wang, S. (2010) · Planta Medica · doi:10.1055/s-0030-1250177 · Cited by 31
樋口, 栄., Oridate, N., Homma, A., Suzuki, F., Atago, Y., Nagahashi, T., Furuta, Y., & Fukuda, S. (2007) · Head & Neck · doi:10.1002/hed.20632 · Cited by 31
Silva, G. P. D. L., & Aboussekhra, A. (2015) · Molecular Carcinogenesis · doi:10.1002/mc.22299 · Cited by 31
Familial Melanoma–Associated Mutations in p16 Uncouple its Tumor-Suppressor Functions
Jenkins, N., Jung, J., Liu, T., Wilde, M., Holmen, S. L., & Grossman, D. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.401 · Cited by 33
“…kinases 4 and/or 6 (CDK4/6) or preassembled CDK4/6-cyclin D complexes (Hirai et al., 1995; Serrano et al., 1993), inhibiting hyperphosphorylation of Retinoblastoma-associated pocket proteins and delaying cell cycle progression from the G1 to S phase (Alcorta et al., 1996; Lukas et al., 1995).”
BackgroundInfluentialJones, C. J., Shaw, J. J., Wyllie, F. S., Gaillard, N., Schlumberger, M. J., & Wynford‐Thomas, D. (1996) · Molecular and Cellular Endocrinology · doi:10.1016/0303-7207(95)03697-0 · Cited by 31
Regulation of cellular senescence by microRNAs
Ma, X., Zheng, Q., Zhao, G., Yuan, W., & Liu, W. (2020) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2020.111264 · Cited by 30
Lv, X., Ye, G., Zhang, X., & Huang, T. (2017) · Medicine · doi:10.1097/md.0000000000008106 · Cited by 33
“Located on human chromosome 9p21, the p16 gene, a family of regulators of the cell cycle, consisting of 3 exons and 2 introns, is a cyclin-dependent kinase inhibitor and plays a key role in cell cycle regulation.([9,10]) The loss of p16 expression through methylation has”
Background
Metadata
- Authors
- Lukas, J., Parry, D., Aagaard, L., Mann, D. J., Bartkova, J., Strauss, M., Peters, G., & Bartek, J.
- Affiliations
- Danish Cancer Society (DK)
- ORCID
- Mann, David J.
- Venue
- Nature
- Published
- 1995-06
- Volume
- 375
- Issue
- 6531
- Pages
- 503-506
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2010493387
- Cited by
- 899
- References
- 28
- Citations by year
- 2026: 9 · 2025: 6 · 2024: 6 · 2023: 7 · 2022: 16 · 2021: 15 · 2020: 14 · 2019: 15 · 2018: 17 · 2017: 16 · 2016: 15 · 2015: 15 · 2014: 14 · 2013: 22 · 2012: 16
- FWCI
- 32.15
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Ophthalmology › Ocular Oncology and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Microtubule and mitosis dynamics
- Keywords
- p16, retinoblastoma protein, CDKN2, tumour suppressor, cell cycle arrest, G1 phase progression, D-type cyclins, CDK4, CDK6, retinoblastoma, carcinogenesis, chromosome 9p21
- MeSH terms
- Animals, Carrier Proteins, Cell Cycle, Cells, Cultured, Cloning, Molecular, Escherichia coli, Humans, Mice, Inbred BALB C, Microinjections, Mutation, Proto-Oncogene Proteins, Recombinant Proteins, Tumor Cells, Cultured, Oncogene Proteins, Genes, Tumor Suppressor, Retinoblastoma Protein, G1 Phase, Cyclins, Protein Serine-Threonine Kinases, Cyclin-Dependent Kinases, Cyclin D1, Cyclin-Dependent Kinase Inhibitor p16, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.